Evidence map›Paper›PMID 26392951›Full record

ArticlePublic health action2012

ART uptake, its timing and relation to anti-tuberculosis treatment outcomes among HIV-infected TB patients.

K C Takarinda, A D Harries, T Mutasa-Apollo, C Sandy, T Murimwa, O Mugurungi

Abstract read
In one paragraph

Article in Public health action, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

K C TakarindaAIDS & TB Unit, Ministry of Health & Child Welfare, Harare, Zimbabwe ; Department of Community Medicine, University of Zimbabwe, Harare, Zimbabwe.
A D HarriesInternational Union Against Tuberculosis and Lung Disease, Paris, France ; London School of Hygiene & Tropical Medicine, London, UK.
T Mutasa-ApolloAIDS & TB Unit, Ministry of Health & Child Welfare, Harare, Zimbabwe.
C SandyAIDS & TB Unit, Ministry of Health & Child Welfare, Harare, Zimbabwe.
T MurimwaAIDS & TB Unit, Ministry of Health & Child Welfare, Harare, Zimbabwe.
O MugurungiAIDS & TB Unit, Ministry of Health & Child Welfare, Harare, Zimbabwe.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

settingAll public health facilities in two provinces of Zimbabwe.

objectiveTo determine, among tuberculosis (TB) patients with human immunodeficiency virus (HIV) registered in 2010, 1) the proportion started on antiretroviral treatment (ART), 2) the timing of ART in relation to the start of anti-tuberculosis treatment, and 3) whether timing of ART influenced anti-tuberculosis treatment outcomes.

designRetrospective cohort study.

resultsOf the 2655 HIV-positive TB patients, 1115 (42%) were documented as receiving ART. Of these, 178 (16%) started ART prior to anti-tuberculosis treatment. Of those who started after anti-tuberculosis treatment, 17% started within 2 weeks, 43% between 2 and 8 weeks and 40% after 8 weeks. Treatment success in the cohort was 82%, with 14% deaths before completion of anti-tuberculosis treatment. Not receiving ART during anti-tuberculosis treatment was associated with lower anti-tuberculosis treatment success (adjusted RR 0.70, 95%CI 0.53-0.91) and more deaths (adjusted RR 3.43, 95%CI 2.2-5.36). There were no differences in TB treatment outcomes by timing of ART initiation.

conclusionART uptake is low given the improved treatment outcomes in those put on ART during anti-tuberculosis treatment. Better integration of HIV and TB services is needed to ensure increased coverage and earlier ART uptake.

Indexed as

antiretroviral treatmentHIVtuberculosisZimbabwe

Identifiers

PMID26392951
PMCPMC4463041

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.